RNS Number : 0965H
Genedrive PLC
05 June 2026

05 June 2026

genedrive plc

("genedrive" or the "Company")

Receipt of R&D tax credit

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, confirms it has received an R&D tax credit refund of approximately £0.76m from HMRC in respect of the financial years ended 30 June 2024 and 30 June 2025.

For further details please contact:

genedrive plc	+44 (0)161 989 0245
Gino Miele: CEO / Russ Shaw: CFO	https://investors.genedrive.com/s/e0025c
Peel Hunt LLP (Nominated Adviser and Broker)	+44 (0)20 7418 8900
James Steel	
5654 & Company (Media & Investor Relations)	genedrive@5654.co.uk
Matthew Neal	+44 (0)7917 800 011
Melissa Gardiner	+44 (0)7757 697357

Subscribe to our news alert service: https://investors.genedrive.com/s/efea03

About genedrive plc (http://www.genedrive.com**).**

genedrive plc is a UK-based, commercial-stage pharmacogenetic testing company focused on rapid, point-of-care diagnostic tests to guide safe and effective drug prescription in emergency and acute care settings.

genedrive's proprietary technology platform enables clinicians to prescribe safer and more effective therapies based on a patient's genetic profile, supporting improved outcomes while reducing pressure on healthcare systems, lowering downstream healthcare costs through the prevention of avoidable complications and earlier, more effective intervention

The Company has two CE-IVD approved and NICE-recommended tests in NHS clinical use. The Genedrive® CYP2C19 ID Kit identifies stroke patients who will not respond to the current standard of care, Clopidogrel, used to reduce risk of secondary stroke. The Genedrive® MT-RNR1 ID Kit helps prevent antibiotic-induced hearing loss (AIHL) in newborns, enabling treatment decisions within actionable timeframes at the point of care.

Headquartered in Manchester, genedrive is focused on scaling UK-developed precision diagnostics within routine care and leveraging real-world evidence to support broader international adoption and commercial growth.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCUPUAUQUPQGQC